Rova-T

Rova-T (rovalpituzumab tesirine) is an investigational antibody drug conjugate targeting the cancer stem cell-associated target delta-like protein 3 (DLL3). It is also being investigated as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a second-line treatment for extensive-stage small cell lung cancer (SCLC).

Type of Molecule

Biologic

Target

DLL3

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Neuroendocrine Tumors n/a
Phase 1
Small Cell Lung Cancer (1L SCLC) n/a
Phase 3